Valeant Pharmaceuticals International, Inc. has entered an agreement to acquire PreCision Dermatology, Inc. for $475 million in cash, plus $25 million for the achievement of sales-based milestones. PreCision develops and markets dermatology products including Locoid, Hylatopic, Clindagel, and BenzEFoam. The transaction is expected to close in 1H14.   PreCision’s two key segments are Onset Dermatologics, which focuses on prescription therapies, and PrecisionMD, which focuses on physician-dispense...